Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anthracyclines | 6 | 2023 | 288 | 2.140 |
Why?
|
Heart Diseases | 6 | 2023 | 2789 | 1.540 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2023 | 692 | 1.480 |
Why?
|
Doxorubicin | 8 | 2023 | 2234 | 1.260 |
Why?
|
Fluorouracil | 4 | 2021 | 1619 | 1.240 |
Why?
|
Myocytes, Cardiac | 6 | 2023 | 1629 | 0.930 |
Why?
|
Myocarditis | 4 | 2022 | 771 | 0.810 |
Why?
|
Neoplasms | 10 | 2023 | 21696 | 0.790 |
Why?
|
Khellin | 2 | 2018 | 5 | 0.770 |
Why?
|
Toxicity Tests | 1 | 2021 | 121 | 0.750 |
Why?
|
Cardiomyopathies | 6 | 2022 | 1912 | 0.740 |
Why?
|
Nucleosides | 1 | 2019 | 138 | 0.660 |
Why?
|
Citric Acid Cycle | 1 | 2019 | 232 | 0.630 |
Why?
|
Cardiovascular Diseases | 10 | 2022 | 15160 | 0.580 |
Why?
|
Cardiotonic Agents | 2 | 2018 | 535 | 0.530 |
Why?
|
Antineoplastic Agents | 6 | 2022 | 13693 | 0.510 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2023 | 1265 | 0.480 |
Why?
|
Immunotherapy | 2 | 2018 | 4446 | 0.430 |
Why?
|
Heart | 4 | 2022 | 4464 | 0.420 |
Why?
|
Zebrafish | 5 | 2020 | 2996 | 0.400 |
Why?
|
Salaries and Fringe Benefits | 2 | 2021 | 264 | 0.320 |
Why?
|
Cardiovascular Agents | 2 | 2023 | 850 | 0.280 |
Why?
|
Risk Assessment | 3 | 2021 | 23336 | 0.220 |
Why?
|
Hemopexin | 1 | 2022 | 33 | 0.220 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.190 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18034 | 0.190 |
Why?
|
Heme | 1 | 2022 | 307 | 0.180 |
Why?
|
American Heart Association | 2 | 2022 | 1057 | 0.180 |
Why?
|
Metabolic Networks and Pathways | 2 | 2018 | 783 | 0.180 |
Why?
|
Heme Oxygenase-1 | 1 | 2022 | 381 | 0.170 |
Why?
|
Cardiac Imaging Techniques | 1 | 2021 | 269 | 0.170 |
Why?
|
Death, Sudden | 1 | 2021 | 302 | 0.170 |
Why?
|
Myocardial Bridging | 1 | 2018 | 11 | 0.160 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2019 | 640 | 0.160 |
Why?
|
Humans | 36 | 2023 | 744366 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11525 | 0.160 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2022 | 500 | 0.160 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 277 | 0.160 |
Why?
|
Coronary Vasospasm | 1 | 2018 | 88 | 0.150 |
Why?
|
Xenobiotics | 1 | 2018 | 73 | 0.150 |
Why?
|
Nitroglycerin | 1 | 2018 | 325 | 0.150 |
Why?
|
Medical Oncology | 2 | 2022 | 2267 | 0.150 |
Why?
|
Autophagy | 2 | 2023 | 1297 | 0.150 |
Why?
|
Cardiology | 2 | 2019 | 1668 | 0.140 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 670 | 0.130 |
Why?
|
Structure-Activity Relationship | 2 | 2020 | 3130 | 0.130 |
Why?
|
Heart Failure | 5 | 2023 | 10895 | 0.130 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2019 | 1572 | 0.130 |
Why?
|
Malate Dehydrogenase | 1 | 2014 | 41 | 0.130 |
Why?
|
Animals | 13 | 2023 | 168768 | 0.120 |
Why?
|
Lymphoma | 1 | 2023 | 1877 | 0.120 |
Why?
|
Troponin | 1 | 2018 | 524 | 0.120 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 3666 | 0.120 |
Why?
|
Anemia, Sickle Cell | 1 | 2022 | 1020 | 0.120 |
Why?
|
Physicians, Women | 1 | 2019 | 486 | 0.110 |
Why?
|
Zebrafish Proteins | 1 | 2020 | 1005 | 0.110 |
Why?
|
Stroke Volume | 3 | 2023 | 5006 | 0.110 |
Why?
|
Metabolomics | 2 | 2019 | 1485 | 0.110 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1240 | 0.110 |
Why?
|
Proteomics | 2 | 2018 | 3638 | 0.100 |
Why?
|
Arrhythmias, Cardiac | 2 | 2022 | 2269 | 0.100 |
Why?
|
Case-Control Studies | 2 | 2020 | 21748 | 0.100 |
Why?
|
Hypotension | 1 | 2018 | 884 | 0.100 |
Why?
|
Breast Neoplasms | 1 | 2019 | 20824 | 0.100 |
Why?
|
Models, Animal | 1 | 2018 | 2173 | 0.100 |
Why?
|
Disease Management | 1 | 2021 | 2460 | 0.090 |
Why?
|
Electrocardiography | 2 | 2021 | 6442 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.090 |
Why?
|
Incidence | 2 | 2019 | 20952 | 0.090 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2018 | 1572 | 0.090 |
Why?
|
Mice | 7 | 2023 | 81201 | 0.090 |
Why?
|
Medicare | 3 | 2022 | 6566 | 0.090 |
Why?
|
Prognosis | 3 | 2019 | 29060 | 0.080 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2540 | 0.080 |
Why?
|
Blood Vessels | 1 | 2014 | 1125 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1968 | 0.080 |
Why?
|
Retrospective Studies | 6 | 2023 | 77460 | 0.080 |
Why?
|
Blood | 1 | 2010 | 598 | 0.080 |
Why?
|
Prospective Studies | 3 | 2021 | 53290 | 0.070 |
Why?
|
Apoptosis | 3 | 2020 | 9724 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2018 | 2073 | 0.070 |
Why?
|
Cardiovascular System | 1 | 2014 | 831 | 0.070 |
Why?
|
Heart Injuries | 1 | 2008 | 210 | 0.070 |
Why?
|
Cells, Cultured | 2 | 2021 | 19233 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3255 | 0.070 |
Why?
|
Biomedical Technology | 1 | 2008 | 220 | 0.070 |
Why?
|
Cell Line | 2 | 2018 | 16000 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2022 | 7882 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7282 | 0.060 |
Why?
|
Female | 12 | 2023 | 380193 | 0.060 |
Why?
|
Risk Factors | 3 | 2020 | 72296 | 0.060 |
Why?
|
Bromocriptine | 1 | 2022 | 111 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 21833 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3514 | 0.050 |
Why?
|
Peripartum Period | 1 | 2022 | 133 | 0.050 |
Why?
|
United States | 4 | 2022 | 69872 | 0.050 |
Why?
|
Aged | 7 | 2023 | 163288 | 0.050 |
Why?
|
Ritonavir | 1 | 2022 | 322 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2023 | 315 | 0.050 |
Why?
|
Prolactin | 1 | 2022 | 669 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5263 | 0.050 |
Why?
|
Heart Block | 1 | 2022 | 410 | 0.050 |
Why?
|
Time Factors | 2 | 2019 | 40075 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2010 | 2897 | 0.040 |
Why?
|
bcl-2-Associated X Protein | 1 | 2020 | 295 | 0.040 |
Why?
|
Niacinamide | 1 | 2020 | 416 | 0.040 |
Why?
|
Mass Spectrometry | 2 | 2018 | 2204 | 0.040 |
Why?
|
Lysosomes | 1 | 2023 | 893 | 0.040 |
Why?
|
Drug Interactions | 1 | 2022 | 1460 | 0.040 |
Why?
|
Male | 10 | 2023 | 350115 | 0.040 |
Why?
|
Sex Factors | 2 | 2021 | 10400 | 0.040 |
Why?
|
Fasting | 1 | 2023 | 1592 | 0.040 |
Why?
|
Kinetics | 2 | 2018 | 6476 | 0.040 |
Why?
|
Proteins | 1 | 2011 | 6100 | 0.030 |
Why?
|
Middle Aged | 6 | 2023 | 213390 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1264 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 63107 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1643 | 0.030 |
Why?
|
Drug Substitution | 1 | 2018 | 281 | 0.030 |
Why?
|
Carbanilides | 1 | 2014 | 17 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2020 | 1549 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4925 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2297 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2020 | 720 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2018 | 976 | 0.030 |
Why?
|
Exercise | 1 | 2010 | 5615 | 0.030 |
Why?
|
Myocardial Infarction | 2 | 2018 | 11718 | 0.030 |
Why?
|
Adult | 4 | 2023 | 214052 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2020 | 1783 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8385 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2086 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2010 | 70 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25039 | 0.020 |
Why?
|
Muscle Contraction | 1 | 2014 | 1235 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12025 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2022 | 9735 | 0.020 |
Why?
|
Myocardium | 1 | 2022 | 4772 | 0.020 |
Why?
|
Isotopes | 1 | 2008 | 124 | 0.020 |
Why?
|
Coronary Sinus | 1 | 2008 | 87 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8091 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7730 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3519 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2737 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2018 | 4576 | 0.020 |
Why?
|
Reference Standards | 1 | 2008 | 1025 | 0.020 |
Why?
|
Models, Cardiovascular | 1 | 2008 | 996 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16367 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8662 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 2010 | 1901 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2011 | 19905 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2023 | 39052 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 29144 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 16690 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15078 | 0.010 |
Why?
|
Rats | 1 | 2008 | 24252 | 0.010 |
Why?
|
Concepts
(157)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(63)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_